Postmortem studies in schizophrenia

Schizophrenia Bulletin

Volumn 24, Issue 3, 1998, Pages 325-341

  Powchik, Peter ^a,b   Davidson, Michael ^b   Haroutunian, Vahram ^b   Gabriel, Stephen M ^b   Purohit, Dushyant P ^b   Perl, Daniel P ^b   Harvey, Philip D ^b   Davis, Kenneth L ^b  

^a PFIZER INC   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Brain pathology; Dementia; Norepinephrine; Serotonin; Synaptic proteins

Indexed keywords

BRAIN PROTEIN; NORADRENALIN; SEROTONIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CINGULATE GYRUS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NEUROPATHOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM;

EID: 0031846540     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a033330     Document Type: Article

References (74)

1. Akbarian, S.; Bunney, W.E.; Potkin, S.G.; Wigal, S.B.; Hagman, J.O.; Sandman, C.A.; and Jones, E.G. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Archives of General Psychiatry, 50:169-177, 1993a.
2. Akbarian, S.; Vinuela, A.; Kim, J.J.; Potkin, S.G.; Bunney, W.E.; and Jones, E.G. Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Archives of General Psychiatry, 50:178-187, 1993b.
3. American Psychiatric Association. DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders. 3rd ed., revised. Washington, DC: The Association, 1987.
4. Arnold, S.E.; Franz, B.R.; Gur, R.C.; Gur, R.E.; Shapiro, R.M.; Moberg, P.J.; and Trojanowski, J.Q. Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions. American Journal of Psychiatry, 152(5):738-748, 1995a.
5. Arnold, S.E.; Franz, B.R.; and Trojanowski, J.Q. Elderly patients with schizophrenia exhibit infrequent neurodegenerative lesions. Neurobiology of Aging, 15(3):299-303, 1994.
6. Arnold, S.E.; Gur, R.E.; Shapiro, R.M.; Fisher, K.R.; Moberg, P.J.; and Gibney, M.R. Prospective clinicopathologic studies of schizophrenia: Accrual and assessment of patients. American Journal of Psychiatry, 152(5):731-737, 1995b.
7. Bajjalieh, S.M., and Scheller, R.H. The biochemistry of neurotransmitter secretion. Journal of Biological Chemistry, 270:1971-1974, 1995.
8. Benes, F.M. Neurobiological investigations in cingulate cortex of schizophrenic brain. Schizophrenia Bulletin, 19(3):537-549, 1993.
9. Benes, F.M.; Majocha, R.; Bird, E.D.; and Marotta, C.A. Increased vertical axon numbers in cingulate cortex of schizophrenics. Archives of General Psychiatry, 44:1017-1021, 1987.
10. Benes, F.M.; McSparren, J.; Bird, E.D.; SanGiovanni, J.P.; and Vincent, S.L. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Archives of General Psychiatry, 48:996-1001, 1991.
11. a receptor binding in superficial layers of cingulate cortex in schizophrenics. Journal of Neuroscience, 12:924-929, 1992.
12. Bleich, A.; Brown, S.L.; Kahn, R.; and van Praag, H.M. The role of serotonin in schizophrenia. Schizophrenia Bulletin, 14(2):297-315, 1988.
13. Bogerts, B. Recent advances in the neuropathology of schizophrenia. Schizophrenia Bulletin, 19(2):431-445, 1993.
14. Breier, A. Clozapine and noradrenergic function: Support for a novel hypothesis for superior efficacy. Journal of Clinical Psychology, 55(Suppl. B):122-225, 1994.
15. Bridge, T.P.; Kleinman, J.E.; Karoum, F.; and Wyatt, R.J. Postmortem central catecholamines and antemortem cognitive impairment in elderly schizophrenics and controls. Neuropsychobiology, 14(2):57-61, 1985.
16. Browning, M.D.; Dudek, E.M.; Rapier, J.L.; Leonard, S.; and Freedman, R. Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics. Biological Psychiatry, 34:529-535, 1993.
17. Bruton, C.J.; Crow, T.J.; Frith, C.D.; Johnstone, E.C.; Owens, D.G.C.; and Roberts, G.W. Schizophrenia and the brain: A prospective cliniconeuropathological study. Psychological Medicine, 20:285-304, 1990.
18. Cole, B.J., and Robbins, T.W. Forebrain norepinephrine: Role in controlled information processing in the rat. Neuropsychopharmacology, 7:129-141, 1992.
19. Csernansky, J.G.; King, R.J.; Faustman, W.O.; Moses, J.A.; Poscher, M.E.; and Faull, K.F. 5-HIAA in cerebrospinal fluid and deficit schizophrenic characteristics. British Journal of Psychiatry, 156:501-507, 1990.
20. Davidson, M.; Harvey, P.H.; Powchik, P.; Parrella, M.; White, L.; Knobler, H.Y.; Losonczy, M.F.; Keefe, R.S.E.; Katz, S.; and Frecska, E. Severity of cognitive impairment in geriatric schizophrenic patients. American Journal of Psychiatry, 152:197-207, 1995.
21. Davidson, M.; Harvey, P.D.; Welsh, K.A.; Powchik, P.; Putnam, K.M.; and Mohs, R.C. Cognitive functioning in late-life schizophrenia: A comparison of elderly schizophrenic patients with Alzheimer's disease. American Journal of Psychiatry, 153(10):1274-1279, 1996.
22. Davidson, M.; Kahn, R.S.; Stern, R.G.; Hirschowitz, J.; Apter, S.; Knott, P.; and Davis, K.L. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Research, 46(2):151-163, 1993.
23. Dennison-Cavanagh, M.E.; Papdopoulos, G.; and Pranavels, J.G. The emergence of the cortical GABAergic neuron: With particular reference to some peptidergic subpopulations. Journal of Neurocytology, 22:805-814, 1993.
24. Devauges, V., and Sara, S.J. Activation of the noradrenergic system facilitates an attentional shift in the rat. Behavioral Brain Research, 39:19-29, 1990.
25. El-Mallakh, R.S.; Kirch, D.G.; Shelton, R.; Fan, K.J.; Pezeshkpour, G.; Kanhouwa, S.; Wyatt, R.J.; and Kleinman, J.E. The nucleus basalis of Meynert, senile plaques, and intellectual impairment in schizophrenia. Journal of Neuropsychiatry and Clinical Neurosciences, 3(4):383-386, 1991.
26. Feinberg, I. Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence? Journal of Psychiatric Research, 17:319-330, 1982.
27. Foley, P.; Hughes, P.D.; Bradford, H.F.; Ghatei, M.A.; Khandanian, N.; and Bloom, S.R. The presence of neuropeptides in GABAergic and cholinergic rat cerebrocortical synaptosome sub-populations. Neuropeptides, 23(2):67-72, 1992.
28. Folstein, M.; Folstein, S.; and McHugh, P. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12:189-198, 1975.
29. Gabriel, S.M.; Bierer, L.M.; Haroutunian, V.; Purohit, D.P.; Perl, D.P.; and Davis, K.L. Widespread deficits in somatostatin but not neuropeptide Y concentrations in Alzheimer's disease cerebral cortex. Neuroscience Letters, 155:116-120, 1993.
30. Gabriel, S.M.; Bierer, L.M.; Purohit, D.P.; Perl, D.P.; and Haroutunian, V. Galanin-like immunoreactivity is increased in the postmortem cerebral cortex from patients with Alzheimer's disease. Journal of Neurochemistry, 62:1516-1523, 1994.
31. Gabriel, S.M.; Davidson, M.; Haroutunian, V.; Powchik, P.; Bierer, L.M.; Purohit, D.P.; Perl, D.P.; and Davis, K.L. Neuropeptide deficits in schizophrenia and Alzheimer's disease cerebral cortex. Biological Psychiatry, 39:82-91, 1996.
32. Gabriel, S.M.; Haroutunian, V.; Powchik, P.; Honer, W.G.; Davidson, M.; Davies, P.; and Davis, K.L. Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia. Archives of General Psychiatry, 54(6):559-566, 1997.
33. Goldman-Rakic, P.S. Working memory dysfunction in schizophrenia. Journal of Neuropsychiatry and Clinical Neurosciences, 6(4):348-357, 1994.
34. Halliday, G.M.; McCann, H.L.; Pamphlett, R.; Brooks, W.S.; Creasey, H.; McCusker, E.; Cotton, R.G.; Broe, G.A.; and Harper, C.G. Brain stem serotonin-synthesizing neurons in Alzheimer's disease: A clinicopathological correlation. Acta Neuropathologica, 84(6):638-650, 1992.
35. Haroutunian, V.; Davidson, M.; Kanof, P.D.; Perl, D.P.; Powchik, P.; Losonczy, M.F.; McCrystal, J.; Purohit, D.P.; Bierer, L.M.; and Davis, K.L. Cortical cholinergic markers in schizophrenia. Schizophrenia Research, 12:137-144, 1994.
36. Harvey, P.D.; Davidson, M.; Powchik, P.; Parrella, M.; White, L.; and Mohs, R.C. Assessment of dementia in elderly schizophrenics with structured rating scales. Schizophrenia Research, 7:85-90, 1992.
37. Honer, W.G.; Hu, L.; and Davies, P. Human synaptic proteins with a heterogeneous distribution in cerebellum and visual cortex. Brain Research, 609:9-20, 1993.
38. Honer, W.G.; Kaufmann, C.A.; and Davies, P. Characterization of a synaptic antigen of interest in neuropsychiatric illness. Biological Psychiatry, 31:147-158, 1992.
39. Honer, W.G.; Kaufmann, C.A.; Kleinman, J.E.; Casanova, M.F.; and Davies, P. Monoclonal antibodies to study the brain in schizophrenia. Brain Research, 500:379-383, 1989.
40. Hughes, C.P.; Berg, L.; Danziger, W.L.; Coben, L.A.; and Martin, R.L. A new clinical scale for the staging of dementia. British Journal of Psychiatry, 14:566-572, 1982.
41. Joseph, M.H.; Baker, H.F.; Crow, T.J.; Riley, G.J.; and Risby, D. Brain tryptophan metabolism in schizophrenia: A post mortem study of metabolites of the serotonin and kynurenine pathways in schizophrenic and control subjects. Psychopharmacology, 62(3):279-285, 1979.
42. Joyce, J.N.; Shane, A.; Lexow, N.; Winokur, A.; Casanova, M.F.; and Kleinman, J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics (see comments). Neuropsychopharmacology, 8(4):315-336, 1993.
43. Kahn, R.S.; Harvey, P.D.; Davidson, M.; Keefe, R.S.E.; Apter, S.; Neale, J.M.; Mohs, R.C.; and Davis, K.L. Neuropsychological correlates of central monoamine function in chronic schizophrenia: Relationship between CSF metabolites and cognitive function. Schizophrenia Research, 11(3):217-224, 1994.
44. Kaneko, M.; Honda, K.; Kanno, T.; Horikoshi, R.; Monome, T.; Wantanabe, A.; and Kumashiro, H. Plasma free 3-methoxy-4-hydroxyphenylglycol in acute schizophrenics before and after treatment. Neuropsychobiology, 25(3):126-129, 1992.
45. Kay, S.R.; Fiszbein, A.; and Opler, L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2):261-276, 1987.
46. Keefe, R.S.E.; Frecksa, E.; Apter, S.H.; Davidson, M.; Macaluso, J.; Hirshowitz, J.; and Davis, K.L. Clinical characteristics of Kraepelinian schizophrenia: Replication and extension of previous findings. American Journal of Psychiatry, 153(6):806-811, 1996.
47. Keshavan, M.S.; Anderson, S.; and Pettegrew, J.W. Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited. Journal of Psychiatric Research, 28(3):239-265, 1994.
48. Kleinman, J.E.; Casanova, M.F.; and Jaskiw, G.E. The neuropathology of schizophrenia. Schizophrenia Bulletin, 14(2):209-216, 1988.
49. Lewis, D.A. The catecholaminergic innervation of primate prefrontal cortex. Journal of Neural Transmission, 36(Suppl.):179-200, 1992.
50. 2+-dependent manner. Trends in Neurosciences, 18(4):177-183, 1995.
51. Maas, J.W.; Contreras, S.A.; Miller, A.L.; Berman, N.; Bowden, C.L.; Javors, M.A.; Seleshi, E.; and Weintraub, S.E. Studies of catecholamine metabolism in schizophrenia/psychosis: II. Neuropsychopharmacology, 8(2):111-116, 1993.
52. Maruyama, Y.; Oshima, T.; and Nakajima, E. Current concepts: III. Simultaneous determination of catecholamines in rat brain by reversed-phase liquid chromatography with electrochemical detection. Life Sciences, 26:1115-1120, 1980.
53. Mirra, S.S.; Heyman, A.; McKeel, D.; Sumi, S.M.; Brain, B.J.; Brownlee, L.M.; Vogel, F.S.; Hughes, J.P.; van Belle, G.; and Berg, L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathological assessment of Alzheimer's disease. Neurology, 41:479-486, 1991.
54. 2 receptors in chronic schizophrenia. Biological Psychiatry, 21(14):1407-1414, 1986.
55. Morris, J.C.; Heyman, A.; Mohs, R.C.; Hughes, J.P.; van Belle, G.; Fillenbaum, G.; Mellits, E.D.; and Clark, C. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology, 39:1159-1165, 1989.
56. Ong, W.Y., and Garey, L.J. Distribution of GABA and neuropeptides in the human cerebral cortex: A light and electron microscope study. Anatomical Embryology, 183(4):397-413, 1991.
57. Pakkenberg, B. Post-mortem study of chronic schizophrenic brains. British Journal of Psychiatry, 151:744-752, 1987.
58. Pakkenberg, B. The volume of the mediodorsal thalamic nucleus and nucleus accumbens in schizophrenia. Schizophrenia Research, 7:95-100, 1992.
59. Potkin, S.G.; Weinberger, D.R.; Linnoila, M.; and Wyatt, R.J. Low CSF 5-hydroxyindoleacetic acid in schizophrenic patients with enlarged cerebral ventricles. American Journal of Psychiatry, 140:21-25, 1983.
60. Powchik, P.; Davidson, M.; Nemeroff, C.B.; Haroutunian, V.; Losonczy, M.; Bissette, G.; Perl, D.P.; Ghanbari, H.; Miller, B.; and Davis, K.L. Alzheimer's disease related protein in geriatric schizophrenic patients with cognitive impairment. American Journal of Psychiatry, 150:1726-1727, 1993.
61. Prohovnik, I.; Dwork, A.J.; Kaufman, M.A.; and Willson, N. Alzheimer-type neuropathology in elderly schizophrenia patients. Schizophrenia Bulletin, 19(4):805-816, 1993.
62. Purohit, D.P.; Davidson, M.; Perl, D.P.; Powchik, P.; Haroutunian, V.; Bierer, L.; McCrystal, J.; Losonczy, M.; and Davis, K.L. Severe cognitive impairment in schizophrenic patients: A clinicopathological study. Biological Psychiatry, 33:255-260, 1993.
63. Rogers, J.H. Immunohistochemical markers in rat cortex: Co-localization of calretinin and calbindin-D28k with neuropeptides and GABA. Brain Research, 587(1):147-157, 1992.
64. Roth, B.L., and Meltzer, H.Y. The role of serotonin in schizophrenia. In: Psychopharmacology: The Fourth Generation of Progress. Bloom, F.E., and Kupfer, D.J., eds. New York, NY: Raven Press, 1995. pp. 1215-1227.
65. Shapiro, R.M. Regional neuropathology in schizophrenia: Where are we? Where are we going? Schizophrenia Research, 10:187-239, 1993.
66. Sollner, T.; Whiteheart, S.W.; Brunner, M.; Erdjument-Bromage, H.; Geromanos, S.; Tempst, P.; and Rothman, J.E. SNAP receptors implicated in vesicle targeting and fusion. Nature, 362:318-325, 1993.
67. Sower, A.C.; Bird, R.D.; and Perrone-Bizzozero, N.J. Increased levels of GAP-43 protein in schizophrenic brain tissues demonstrated by a novel immunodetection method. Molecular and Chemical Neuropathology, 24(1):1-11, 1995.
68. Stern, Y.; Gurland, B.; Taternichi, T.K.; Tang, M.; Wilder, D.; and Mayeux, R. Influence of education and occupation on the incidence of Alzheimer's disease. Journal of the American Medical Association, 271:1004-1010, 1994.
69. Tamlyn, D.; McKenna, P.J.; Mortimer, A.M.; Lund, C.E.; Hammond, S.; and Baddeley, A.D. Memory impairment in schizophrenia: Its extent, affiliations and neuropsychological character. Psychological Medicine, 22:101-115, 1992.
70. Unger, J.W., and Lange, W. NADPH-diaphorase-positive cell population in the human amygdala and temporal cortex: Neuroanatomy, peptidergic characteristics and aspects of ageing and Alzheimer's disease. Acta Neuropathologica, 83:636-646, 1992.
71. van Kammen, D.P.; Agren, H.; Yao, J.K.; O'Connor, D.T.; Gurklis, J.; and Peters, J.L. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. American Journal of Psychiatry, 151(3):379-384, 1994.
72. Vincent, S.R.; Johansson, O.; Hokfelt, T.; Skirboll, L.; Eide, R.P.; Terenius, L.; Kimmel, J.; and Goldstein, M. NADPH-diaphorase: A selective histochemical marker for striatal neurons containing both somatostatin-and avian pancreatic polypeptide (APP)-like immunoreactivities. Journal of Comparative Neurology, 217(3):252-263, 1983.
73. Weinberger, D.R. A connectionist approach to the prefrontal cortex. Journal of Neuropsychiatry and Clinical Neurosciences, 5:241-253, 1993.
74. Weinberger, D.R.; Berman, K.F.; and Illowsky, B.P. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: III. A new cohort and evidence for a monoaminergic mechanism. Archives of General Psychiatry, 89:49-59, 1988.